IDEAYA Biosciences Inc. (IDYA)
NASDAQ: IDYA
· Real-Time Price · USD
23.93
-0.44 (-1.81%)
At close: Aug 15, 2025, 10:18 AM
-1.81% (1D)
| Bid | 23.85 |
| Market Cap | 2.1B |
| Revenue (ttm) | 7M |
| Net Income (ttm) | -331.03M |
| EPS (ttm) | -3.84 |
| PE Ratio (ttm) | -6.23 |
| Forward PE | -6.97 |
| Analyst | Buy |
| Ask | 23.93 |
| Volume | 157,746 |
| Avg. Volume (20D) | 1,134,540 |
| Open | 24.41 |
| Previous Close | 24.37 |
| Day's Range | 23.84 - 24.54 |
| 52-Week Range | 13.45 - 40.74 |
| Beta | 0.09 |
About IDYA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IDYA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IDYA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
IDEAYA Biosciences Inc. is scheduled to release its earnings on
Nov 3, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+2.12%
IDEAYA Biosciences shares are trading higher after...
Unlock content with
Pro Subscription
3 weeks ago
+5.08%
IDEAYA Biosciences shares are trading higher after the company announced the results from a multi-site global Phase 2 study of neoadjuvant darovasertib in primary uveal melanoma was accepted for a Proffered Paper oral presentation at the 2025 European Society of Medical Oncology meeting.
